BGB-3111_BGB-A317_Study_001

Completed

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Beigene Study ID info

BGB-3111_BGB-A317_Study_001

ClinicalTrials.gov ID info

Clinical Drug Trials ID info

CTR20180193

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

You are now leaving BeiGene Australia


BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL